No Data
No Data
Individual stock information.
Oncolys BioPharma's tumor lysis adenovirus "OBP-301", for which the company had filed a patent application, has received patent examination approval domestically in Japan. The patent term is until May 2040. There are plans to submit approval applications for "OBP-301" as a regenerative medical product for esophageal cancer treatment within the current December period. After a morning rise, the stock price showed a decline. Basis's stock has significantly increased, updating last year's high. Every year on June 30 and December 31.
Oncolys BioPharma: Business briefing materials
Soft trends and a decline in U.S. stocks are burdensome, but there may be a firm bottom in the market.
[Emerging Markets Individual Stock Global Strategy] Today's Emerging Markets are expected to experience a sluggish development. In yesterday's U.S. Stock market on the 26th, the Dow Inc fell by 132.71 points (-0.31%) to 42,454.79, reversing a four-day trend. The uncertainty surrounding 'reciprocal tariffs', strengthened semiconductor regulations in China, and the rise in long-term interest rates following the warning from the St. Louis Fed President about the risks of persistent inflation all weighed on stock prices. Today, selling is likely to dominate the Emerging Markets.
＜Today's individual materials＞ Veru Inc, Iore, Resonac, and Dainippon Ink and Chemicals, etc. (Announcement on the 26th)
▽Liberata <4935.T> has obtained a patent in Japan for the "clothing cooling mist" developed in collaboration with Taffrey International, related to the "cooling agent composition". ▽Iore <2334.T> has started a new business in Cryptos financial services and an Artificial Intelligence (AI) Datacenter business. ▽Resonac <4004.T> expects a significant decrease in operating profit for the fiscal year ending December 2025 (IFRS). ▽Dainippon Seika <4116.T> has projected a net profit for the consolidated fiscal year ending March 2025.
Iore, Oncoris Bio and others.
＜143A＞The shares of Repsel, which is engaged in the Ishin HR consulting business, have been acquired and turned into a subsidiary. ＜1436＞A partial change to the Green Energy shareholder benefits program. ＜166A＞Tasaki HD has a large exercise of the first subscription rights (with exercise price adjustment clauses) starting from the 4th, with the number of shares to be delivered at 1 million shares. ＜2334＞Iole is starting a new business by issuing new shares through a third-party allocation (0.5 million shares) and issuing the 12th subscription rights (with potential shares numbering 0.15 million shares, and a fundraising amount of approximately 0.15 billion yen). ＜4068＞Basis shareholders.
Key points of attention for PTS on the 26th = Imagineer, Basis, Yamaha, ETC.
▽ Imaginia <4644.T> has raised its consolidated net profit Financial Estimates for the fiscal year ending March 2025, and has also increased its Dividends Financial Estimates. ▽ Basis <4068.T> has introduced a shareholder incentive program. ▽ Yamaha <7951.T> has announced its stock buyback. ▽ Oncoress B <4588.T> has received a patent grant for a patent related to the administration method of 'tumor lytic virus OBP-301'. ▽ Isin <143A.T> is set to make human resources consulting firm Repser a subsidiary. ▽ Quest <2332.T> is developing a business application.